N-oleoyl-dopamine decreases muscle rigidity induced by reserpine in rats

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 1, 2009, Pages 21-28

  Konieczny, J ^a   Przegalinski E ^a   Pokorski, M ^b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Muscle rigidity; N oleoyl dopamine; Reserpine

Indexed keywords

HALOPERIDOL; LEVODOPA; METIROSINE; MUSCLE RELAXANT AGENT; N OLEOYLDOPAMINE; RESERPINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANKLE; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; ELECTROMYOGRAM; LOW DRUG DOSE; MALE; MUSCLE FUNCTION; MUSCLE RELAXATION; MUSCLE RIGIDITY; MUSCLE TONE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; WISTAR RAT;

EID: 62649141464     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200104     Document Type: Article

References (25)

1. Pokorski M, Matysiak Z, Marczak M, Ostrowski RP, Kapuściński A, Matuszewska I, Kańska M, Czarnocki Z. Brain uptake of radiolabeled N-oleoyl- dopamine in the rat. Drug Develop Res 2003; 60: 217-24.
2. Bezuglov V, Bobrov M, Gretskaya N, et al. Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine. Bioorg Med Chem Lett 2001; 11:447-9.
3. Chu CJ, Huang SM, De Petrocellis L, et al. N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J Biol Chem 2003; 278:13633-9.
4. Przegaliński E, Filip, M, Zajac D, Pokorski M. N-oleoyl-dopamine increases locomotor activity in the rat. Int J Immunopathol Pharmacol 2006; 19:997-904.
5. Lorenc-Koci E, Wolfarth S, Ossowska K. Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity. Exp Brain Res 1996; 109: 268-76.
6. Johnels B, Steg G, Ungerstedt U. A method for mechanographical recording of muscle tone in the rat: the effect of some antiparkinsonian drugs on rigidity induced by reserpine. Brain Res 1978; 140: 177-81.
7. Colpaert FC. Pharmacological characteristics of tremor, rigidity and hypokinesia, induced by reserpine in rat. Neuropharmacology 1987; 26:1431-40.
8. Wolfarth S, Kolasiewicz W, Ossowska K, Bober M. Direct mechanomyographic measurement of the myorelaxant action of baclofen and diazepam in normal and reserpinized rats. Naunyn Schmiedebergs Arch Pharmacol 1992; 345:209-12.
9. Lorenc-Koci E, Ossowska K, Wardas J, Wolfarth S. Does reserpine induce parkinsonian rigidity? J Neural Transm Park Dis Dement Sect 1995; 9:211-23.
10. Mortimer JA, Webster DD. Evidence for a quantitative association between EMG stretch responses and Parkinsonian rigidity. Brain Res 1979; 162:169-73.
11. Lee RG. Pathophysiology of rigidity and akinesia in Parkinson's disease. Eur Neurol 1989; 29(S1):13-8.
12. Bisogno T, Melck D, Bobrov MYu, Gretskaya NM, Bezuglov VV, De Petrocellis L, Di Marzo V. N-acyl-dopamines: novel synthetic CB(1) cannabinoid- receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 2000; 351:817-24.
13. Zajac D, Matysiak Z, Czarnocki Z, Pokorski M. Membrane association of N-oleoyl-dopamine in rat brain. J Physiol Pharmacol 2006; 57(S4):403-8.
14. Marinelli S, Di Marzo V, Berretta N, Matias I, Maccarrone M, Bernardi G, Mercuri NB. Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J Neurosci 2003; 23:3136-44.
15. Mezey E, Tóth ZE, Cortright DN, et al. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci USA 2000; 97:3655-60.
16. Dawbarn D, Harmar AJ, Pycock CJ. Intranigral injection of capsaicin enhances motor activity and depletes nigral 5-hydroxytryptamine but not substance P. Neuropharmacology 1981; 20:341-6.
17. Di Marzo V, Lastres-Becker I, Bisogno T, De Petrocellis L, Milone A, Davis JB, Fernandez- Ruiz JJ. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Eur J Pharmacol 2001; 420:123-31.
18. Lee J, Di Marzo V, Brotchie JM. A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L- DOPA induced locomotion in normal and reserpine- treated rats. Neuropharmacology 2006; 51:557-65.
19. Schwarz M, Nolden-Koch M, Purr J, Pergande G, Block F. Antiparkinsonian effect of flupirtine in monoamine-depleted rats. J Neural Transm 1996; 103:581-90.
20. 2+ concentration. Eur J Pharmacol 1995; 294:469-73.
21. Brooks JW, Pryce G, Bisogno T, et al. Arvanil- induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors. Eur J Pharmacol 2002; 439:83-92.
22. Lorenc-Koci E, Wolfarth S. Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats. Eur J Pharmacol 1999; 385:39-46.
23. Kobayashi T, Araki T, Itoyama, Y, Takeshita M, Ohta T, Oshima Y. Effects of L-dopa and bromocriptine on haloperidol-induced motor deficits in mice. Life Sci 1997; 61:2529-38.
24. De Ryck, M, Schallert T, Teitelbaum P. Morphine versus haloperidol catalepsy in the rat: a behavioral analysis of postural support mechanisms. Brain Res 1980; 210:143-72.
25. Brown RG, Jahanshahi M. Cognitive-motor dysfunction in Parkinson's disease. Eur Neurol 1996; 36(S1):24-31.